Project Details


PROJECT SUMMARY/ABSTRACT The AIDS Malignancy Consortium (AMC) was established in 1995 and has been at the forefront of the clinical evaluation of interventions for the treatment and prevention of malignancies in people living with the human immunodeficiency virus (PLWH). AMC also studies the biology of cancers and precancerous lesions in PLWH in the context of its clinical trials, providing new insights on further improving the treatment and prevention of cancer. The AMC has conducted over 100 clinical trials, surveys and laboratory studies involving over 8700 patients with HIV- associated cancers and precancerous lesions since its inception, including application of precision therapeutics and immunotherapy, impacting the standard of care for PLWH and cancer. AMC has established a network of 42 core clinical trial sites in the United States, Africa, and Latin America uniquely qualified carry out its mission, created a network of translational scientists and their research laboratories that support AMC clinical trials, and developed a career enhancement program that has fostered a new generation of physicians and scientists with unique expertise in HIV-associated cancers. Expansion of AMC to clinical trials sites in sub- Saharan Africa and Latin America is designed to address regions of the world where the epidemic of HIV and cancer has grown substantially, thereby amplifying the potential clinical impact of its work to a global scale. AMC has also actively engaged PLWH and cancer survivors in its scientific planning and community outreach in order to identify the needs of the community, and disseminate information about AMC and its completed and ongoing research. The participation of many of the key clinicians and clinical researchers, laboratory scientists, and community representatives has made AMC the principal clinical trials group in the world dedicated to improving the treatment and prevention of cancers in this population. We propose to continue and expand our domestic and international clinical trials work in these areas, including the ANCHOR trial; ANCHOR is a large randomized study investigating the role of routine screening for and treatment of high-grade anal squamous intraepithelial lesions, with the goal of preventing development of invasive anal cancer and the morbidity and mortality associated with its diagnosis and treatment, thereby establishing new diagnostic and therapeutic paradigm.
Effective start/end date25/09/1531/08/23


  • National Cancer Institute: $22,174,220.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.